It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Fycompa Hits Primary Endpoint in Monotherapy PIII, Eisai Eyes Filing by March-End
November 29, 2018
- Daiichi Sankyo, Roche to Collaborate on CDx Development for DS-8201
November 29, 2018
- JCR Launches Japan’s 1st Fabrazyme Biosimilar
November 29, 2018
- Daiichi Sankyo’s Herceptin Biosimilar Hits Shelves, Nippon Kayaku/Celltrion Earn Breast Cancer Nod
November 29, 2018
- Takeda’s Brigatinib Bags European OK for 2nd Line ALK-Positive NSCLC
November 29, 2018
- Dissident Shareholder Group Hails Ex-Takeda Chief’s Opposition to Shire Deal
November 29, 2018
- Blincyto, Eybelis Now Available in Japan
November 28, 2018
- Ono Submits Cancer Cachexia Treatment in Japan
November 28, 2018
- Pola Orbis to Transfer All Shares of Pola Pharma to Sun Pharma Global, Aiming to Focus on Beauty Care Business
November 28, 2018
- Sumitomo Dainippon Settles Latuda Patent Lawsuits in US, New 5-Year Biz Plan Due Out Next Spring
November 28, 2018
- Keytruda Continues to Close in on Opdivo in July-September Global Sales
November 27, 2018
- Poteligeo Approved in Europe for Mycosis Fungoides, Sézary Syndrome: Kyowa Kirin
November 27, 2018
- HIV Drug Juluca Gets Japan Approval: ViiV
November 27, 2018
- GSK, Kyowa Kirin Join Hands for HIF-PH Inhibitor Daprodustat
November 26, 2018
- Astellas Grabs License to Gene Therapy JVS-100, with Acquisition also in Cards
November 26, 2018
- Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Earns FDA’s Priority Review Status
November 26, 2018
- Dissident Takeda Shareholders Making Final Pitch to Thwart Shire Buyout
November 26, 2018
- MHLW Approves Label Expansions for Praluent, Tremfya
November 22, 2018
- Mundipharma Obtains Exclusive Rights in Japan from South Korean Firm for Osteoarthritis Cell Therapy
November 22, 2018
- Takeda Voluntary Recalls 7 Narcotic Injectable Products after Confirming Coloring
November 22, 2018
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…